Home > BIGG > Search result

    Results: 3

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged 19–64 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)

    MMWR recomm. rep; 72 (3), 2023
    On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
    Heptavalent Pneumococcal Conjugate Vaccine/immunology, Immunocompromised Host, Cochlear Implantation, Cerebrospinal Fluid Leak
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) of Pneumococcal Vaccines for Immunocompromised Children Aged 6 through 18 Years

    MMWR recomm. rep; 62 (25), 2013
    GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question...
    Pneumococcal Vaccines/therapeutic use, Immunocompromised Host, Pneumococcal Infections/immunology, Anemia, Sickle Cell/immunology, HIV Infections/immunology, Immunogenicity, Vaccine
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Immunocompromised Adults

    MMWR recomm. rep; 61 (40), 2012
    GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for routine use among immunocompromised adults. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods...
    Pneumococcal Vaccines/therapeutic use, Pneumococcal Infections/immunology, Immunocompromised Host, Immunogenicity, Vaccine
    Fulltext